Agilisium has invested Rs 50 crore to help pharmaceutical, biotech, and medical technology companies operationalise artificial intelligence, introducing a new professional standard called Forward Deployment Experts (FDX).
The US Food and Drug Administration's (USFDA)'s new draft guidelines aimed at speeding up and reducing the cost of developing biosimilars - lower-priced, near-replicas of complex biologic medicines - could significantly benefit Indian biotech companies.
Restoring weighted tax deductions and adopting a petty patents regime can foster firm-level innovative activity critical for competitiveness, points out Nagesh Kumar.
Asia takes the lead, boasting four Indian cities on the list, according to the 2024 Savills Growth Hubs Index.
'Our problem is not a budget deficit but a trust deficit. We need to trust our institutions and industries to innovate and lead. That is the way forward for India.'
Among the Sensex firms, State Bank of India, Maruti Suzuki India, Axis Bank, NTPC, BEL, Adani Ports, Eternal, Sun Pharmaceuticals, Power Grid, ITC, UltraTech Cement, Trent, HCL Technologies, Mahindra & Mahindra, and HDFC Bank were the major gainers. On the other hand, Tata Steel, Tata Consultancy Services, Tech Mahindra, Titan, Bajaj Finserv, Tata Motors, Bharti Airtel and Bajaj Finance were among the laggards.
If the Indian government is indeed serious about reversing brain drain, it needs to put much more emphasis on research and innovation, especially in areas that will determine the future, asserts Prosenjit Datta.
Delhi-based pharma major Mankind Pharma on Wednesday announced a collaboration with OpenAI to institutionalise artificial intelligence (AI) across its value chain, making it one of the first few Indian pharmaceutical companies to fully integrate advanced AI into its core operations.
Concerns over weakening demand for Indian pharmaceutical (pharma) drugs in the US - their largest export market - have weighed heavily on investor sentiment this year. While the Nifty 50 has gained 6.02 per cent year - to - date (as on September 15), the Nifty Pharma index has declined 5.18 per cent, National Stock Exchange data shows.
Fresher hiring grew by 8 per cent driven by non-IT services oil and gas, real estate, and education sectors.
Showcasing India as an attractive investment destination, Modi said the country has political and economic stability as well as transparency and predictability in policy decisions.
Procter & Gamble has announced Shailesh Jejurikar as its next CEO, effective January 1, 2026. Jejurikar, an India-born executive, will succeed Jon Moeller in the role.
The $1.2 billion in-space manufacturing market is expected to grow and be worth more than $20 billion by 2033.
The edited sheep contains no foreign DNA, distinguishing it from transgenic organisms and paving the way for regulatory approval under India's evolving biotech policy framework.
India's pharmaceuticals and medical devices industries are still hopeful that trade negotiations with the US could cut a fairer deal for both sides, after President Donald Trump announced a 25 per cent tariff rate on India on a social networking platform without divulging the finer details.
After reports claimed that filings in patent offices in India, the US, and Europe did not mention ICMR or its scientists, but only BBIL and its scientists, the Hyderabad-based biotechnology (biotech) company clarified that in the "rush" to develop vaccines and file appropriate patents, BBIL had missed adding ICMR's name in the original filings.
From tackling visa woes to admission counselling, rediffGURU Dr Karan Gupta helps you choose the right course and country to study abroad.
Karnataka Chief Minister Siddaramaiah alleged that the rushed approval and distribution of the COVID-19 vaccine may be a contributing factor to cardiac arrest deaths, citing several international studies that recently suggested a possible link between the vaccines and a rise in heart attacks.
Mumbai-based pharma major Wockhardt, which is gearing up to launch its promising antibiotic candidate Zaynich soon, on Friday announced a shift in its United States (US) operations. The Indian pharma giant revealed that it has decided to exit the generics pharmaceutical segment in the country.
'If you align your ambition with India's rise, the peak of your careers will unfold alongside the peak of India's power.'
rediffGURU Dr Ganesh Natarajan offers advice on how to build and scale your first start-up.
Justice Dinesh Pathak, allowing a writ petition filed by M/s Marion Biotech Private Limited, observed that he was surprised that Indian authorities are "trying to validate their proceedings" based on the judgement of the Supreme Court of the Republic of Uzbekistan.
The fraud is alleged to have caused a Rs 65 crore loss to the Brihanmumbai Municipal Corporation (BMC).
Dr Karan Gupta offers guidance on how to pick the right international course and university.
Success in this space demands more than luck, it requires sharp analysis, disciplined execution, and understanding market movers.
'In the Indian government there are no illusions about the United States reliability or the possibility of having any kind of preferential treatment from Washington when it comes to trade.'
The two directors of the company named in the FIR, however, still remain at large.
Computer science has been an evergreen choice among engineering aspirants. However, with the rise in AI, students are increasingly realising the potential of automation and robotics.
While advancements in biotechnology hold immense promise for health and innovation, they also come with significant risks if misused.
'iNCOVACC' is priced at Rs 800 for private markets and at Rs 325 for supplies to the government of India and state governments.
The BJP received the highest amount in large donations among national parties in the financial year 2023-24, with over Rs 2,243 crore declared from 8,358 donations, according to a report by poll rights body the Association for Democratic Reforms (ADR). The report, based on data submitted to the Election Commission, highlighted trends in political donations above Rs 20,000. The total declared donations to national parties stood at Rs 2,544.28 crore from 12,547 contributions - a sharp 199 per cent increase compared to the previous year.
India witnessed a record-breaking surge in deal activity in February, with 226 M&A and private equity deals totaling $7.2 billion -- the highest monthly deal volume in the last three years, according to the Dealtracker report of Grant Thornton Bharat. "This represents a 67 per cent increase in volumes and a 5.4-fold increase in values compared to February 2024, while a 14 per cent increase over the previous month," it said.
Bharat Biotech is targeting to manufacture one billion doses of its intra-nasal vaccine in 2022 which is under clinical trials now.
The drug maker will lose some incentives if its membership is suspended, sources in Pharmexcil said.
The termination of the pact comes after the deal with the Brazilian government for supply of 20 million doses of the vaccine landed in controversy and attracted investigation by authorities in that country.
According to sources close to ANI, "Bharat Biotech has informed Union health ministry that it will rectify the issues pointed out by WHO in 15 to 20 days." "World Health Organisation (WHO)'s suspension is not related to safety or efficacy issues but limited only to supply for United Nations agencies."
iNCOVACC is the world's first intranasal vaccine for COVID-19 to receive approval for the primary two-dose schedule, and as a heterologous booster dose.
"We have received feedback that certain immunisation centres are recommending taking three paracetamol 500 mg tablets along with Covaxin for children. No paracetamol or painkillers are recommended after being vaccinated with Covaxin," Bharat Biotech said in a Twitter post.
The company is developing a peptide, which inhibits the coronavirus from infecting the human cell, expects to launch clinical trials in Britain this summer, he added.
Simplifying investment policies at the micro level and introducing a time-bound framework will be critical for India's growth targets, notes Krishna Ella.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances